Explore.Target.Build.

What nature has kept secret for millions of years, we can now uncover in a single high-throughput experiment.

Our technology harnesses the power of genetics and AI to learn the biophysical parameters governing protein function.

Our team

Ben LehnerChief Scientific Advisor & co-founder

Head of Generative and Synthetic Genomics, Wellcome Sanger Institute; ICREA Professor, CRG and Fellow of the Royal Society“we’re going beyond what we can do in academia and having a lot of fun at the same time”

Júlia DomingoCEO & co-founder

Biologist, bioinformatician and coinventor of the ALLOX experimental platform“proud to realize the revolutionary potential of our technology and test the core thesis of our research in the clinic”

André FaureCDO & co-founder

Engineer, computational biologist and coinventor of the ALLOX computational platform“passionate about working on truly disruptive technology at the intersection between AI and biology”

Pablo BaezaCSO & co-founder

Computational biochemist, data scientist and deep mutagenesis guru“the coolest thing about what we’re doing is the potential it has to improve the lives of millions of patients”

Mireia SeumaSenior Scientist

Biochemist and biotechnologist with extensive experience in high-throughput mutagenesis techniques"on a mission to innovate at ALLOX and scale up discovery of allosteric sites from tens to hundreds to thousands"

Emilio Erazo-FischerChief Business Officer

Neuroscientist, Operating Partner at Asabys Partners and former Director of Global BD&L at Boehringer Ingelheim"building stimulating relationships with pharma and biotech to maximize the transformative potential of our technology"

Cristina LorcaResearch Associate

Pharmacist specialized in biotechnology, molecular and cell biology"excited to combine cutting-edge molecular biology with innovative drug development strategies in a team that's passionate about making a difference"

Sol AdaglioResearch Associate

Biotechnologist specialized in molecular and microbiology"driven by the opportunity to apply my experience in biotechnology to research that has the potential to reshape healthcare"

Victoria MalavéOffice Administrator

Business Administration specialist with Human Resources experience in fast-paced industries"a great privilege to be part of the ALLOX family and support the team to push scientific boundaries"

Pilar CasadoChief Financial Officer

Business Administration graduate, former Deloitte auditor and La Perla EMEA CFO and Business Partner; 7+ years serving as CFO for biotech startups

We are a team of explorers and builders passionate about revolutionising drug discovery.

Boldness

Ingenuity

Determination

Teamwork

Openness

Fairness

Join us

At ALLOX the success of our revolutionary scientific approach is as important to us as our mission to create a healthy, honest and respectful culture, both internally and with our partners.

We believe that — as in other living systems — team robustness and evolvability are a consequence of diversity, and that individuals thrive when they’re empowered with freedom and responsibility.

If you’re excited about the prospect of working with us, get in touch!

News

The surprisingly simple genetic architecture of protein stability

In research published in Nature, André Faure and Professor Ben Lehner – co-founders of ALLOX – have discovered that the impact of mutations on protein stability is more predictable than previously thought.

2024-10-23|NEWS COVERAGE

Júlia Domingo, CEO of ALLOX, interviewed by El·lipse magazine

Júlia explains how the company was born at the CRG, how the technology they developed works, and what its future holds.

2024-07-09|NEWS COVERAGE

ALLOX to present at EMBO | EMBL AI and biology Symposium

André Faure, ALLOX Co-founder and CDO, will present at the EMBO | EMBL AI and biology Symposium, on Wednesday, March 13th at 14:15.

2024-03-09|EVENTS

Get in touch

For all enquiries, send us a message here or email us at hello@allox.bio. We look forward to hearing from you!

Name*

E-mail*

Content*

Investors

This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.

Grants

Grant PTQ2023-013021 awarded by MCIU/AEI/10.13039/501100011033

Centre for Genomic Regulation (CRG)

C/ Dr. Aiguader, 88, PRBB Building,

08003 Barcelona, Spain